Archive: February 2017

Barriers to the Development of Drugs for Primary Brain Tumors

Susan M. Chang, MD

  H&O  What are the most common types of primary brain tumors? SC  The most common types are meningioma, tumors that arise in the lining of […]

Is There a Role for Single-Agent BRAF Inhibition in Melanoma?

Bartosz Chmielowski, MD, PhD

  H&O  What makes BRAF inhibition a good approach to the treatment of melanoma? BC  BRAF inhibitors, especially when combined with MEK inhibitors, are an excellent […]

Manifestations and Management of Veno-occlusive Disease/Sinusoidal Obstruction Syndrome in the Era of Contemporary Therapies

Priti Tewari, MD, Whitney Wallis, PharmD, and Partow Kebriaei, MD

  Abstract: The concept of veno-occlusive disease (VOD), along with our understanding of it, has historically been and remains an evolving phenomenon. This review presents a […]

Evolving Standards of Care for Resected Pancreatic Cancer

Benjamin A. Weinberg, MD, Philip A. Philip, MD, PhD, and Mohamed E. Salem, MD

    Abstract: Pancreatic cancer is a devastating illness, and surgical resection offers the only chance of a cure for patients with the disease. Relatively few […]

Highlights in Gene Therapy and Alternative Therapies in Nonmalignant Hematology From the 2016 American Society of Hematology Meeting

  Highlights in Gene Therapy and Alternative Therapies in Nonmalignant Hematology From the 2016 American Society of Hematology Meeting December 3-6, 2016 • San Diego, California […]

The Role of Regorafenib in Hepatocellular Carcinoma

Catherine T. Frenette, MD

  H&O  What is the mechanism of action of regorafenib? CF  The mechanism of action of regorafenib (Stivarga, Bayer) is very similar to that of sorafenib […]

An Interim Analysis of the ZUMA-1 Study of KTE-C19 in Refractory, Aggressive Non-Hodgkin Lymphoma

Sattva S. Neelapu, MD

  H&O  What are the current treatment approaches for patients with refractory aggressive DLBCL? SN The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL) is […]

The Future of Immunotherapy as Perioperative Therapy in Renal Cell Carcinoma

Reports from the International Kidney Cancer Symposium November 5-6, 2016, Miami, Florida Researchers are launching 2 new studies of checkpoint inhibitors as perioperative treatment for patients with […]

Letter From the Editor: Inauguration Week

Brad S. Kahl, MD

  At a dinner party, you should never discuss politics or religion. The same probably holds true for Letters From the Editor. Here I go anyway. […]

Back to Archive